



Best Practices for Managing the Life-Cycle of an Investigator Initiated Trial

Gurveen Saberwal, Ph.D.
Former Program Manager, Investigator Initiated Research,
Oncology and Immunology, Shire

Investigator Initiated Research

Investigator Initiated Research (IIR/IIS/IISR/IIT) is defined as unsolicited, independent research where the investigator or the Institution (academic, private, or governmental) serves as the Sponsor and a pharmaceutical or medical device company provides support in the form of study drug/device and/or funding

Sponsor

- Sponsor is the person or organization who takes responsibility for and initiates a clinical investigation. The Sponsor does not actually conduct the investigation unless the Sponsor is a Sponsor-Investigator

Objectives



- Establish an IIT strategy
- Optimize the proposal submission and review process
- Define contract milestones that will ensure the smooth execution of an IIT
- Manage strong relationships with external investigators while maintaining compliance

Overview

Establish an IIT Strategy

Optimize Submission and Review Process

Define Contract milestones for smooth execution

Manage strong relationships with external investigators while maintain compliance

Conclusions

Overview

Establish an IIT Strategy

Optimize Submission and Review Process

Define Contract milestones for smooth execution

Manage strong relationships with external investigators while maintain compliance

Conclusions

Strategy for IIT is created under overall GMA plan to better understand benefit/risk profiles of Company's therapies and also address unmet medical needs

- Medical Team-
 - Understanding pre-clinical data
 - Develop IIT Strategy/create a medical plan

- Limit overlap with Company sponsored strategy/studies
 - Should try to not have patient overlap as well

- Consideration of life cycle management
 - Resources
 - Drug supply
 - Budget considerations

IIT STRATEGY: AREAS OF INTEREST (AOIs)



- AOIs are then created under IIT Strategy-For website
 - Detailed AOIs
 - Detailed: Less proposals, very focused
 - Brief/Broad AOIs
 - Broad: More proposals to choose from and provides flexibility
- Detailed AOI documents prepared to train field medical personnel for unsolicited discussion with KOLs/external investigators
 - Gaps by indication/across program (areas of higher interest)
 - In scope/out of scope

IIT STRATEGY: Prioritization of Products



- Medical Teams plan product strategies for IIRs depending on where they are with life cycle of the product
- This could be based on company's priorities on brands/products
 - Product being launched- High priority
 - Older products might have lower priority
 - Explore use of a marketed drug for new indications, in new populations, in new dosages regimes or in new combinations with other treatments
 - Evaluate biomarkers that could be useful in diagnostic tests or treatment management

IIT STRATEGY: Budget Planning



- Plan for yearly budget based on branding priorities
 - Committed amount for ongoing studies
 - Easier to control committed funds
 - New IIRs
 - Based on IIR Strategy/product priorities of company
 - Previous years' budget allocations/spend

IIT STRATEGY: Company Partnerships

- Partnerships with other companies as part of licensing deals may have an impact on the rights and process for approval and support of IIT studies in certain countries
 - Some products are developed in partnerships
 - Collaboration with partner company on IIT strategy by Medical Teams
 - Budgeting for partnership IITs dependent on company strategy
 - **Separate strategy/geographical areas**
 - **Shared budget**

IIT STRATEGIES: Acquisitions

- Products acquired for a specific TA/Franchise
 - IIT strategy could be based on the M&A agreement between the companies
 - Based on contractual status of acquired ongoing IIRs
- Usually acquired from smaller companies where the processes are not very detailed/established
- In addition to amendment per new company policy, there is also a need to honor the commitment made by acquired company to the Investigators/Institutions

Overview

Establish an IIT Strategy

Optimize Submission and Review Process

Define Contract milestones for smooth execution

Manage strong relationships with external investigators while maintain compliance

Conclusions

OVERVIEW



- Submission via Portal
- Different timelines for submission
 - Windows
 - Rolling submission
- Windows submission
 - Once/twice a year or more
 - Cross functional committee reviews all proposals together with a set budget
 - Utilize submission portal website/field team

Rolling Submissions - Process

- Applications accepted throughout the year via submission portal website
 - Timeframes for review meetings communicated on the website
- Brief Applications
 - Decision provided with 45 days of submission
 - No funding decisions
- Full Applications
 - Quarterly review meetings for decision on funding
 - Medical Affairs team reviews with input/feedback as required from cross functional team

Window Submissions

- Advantages:
 - Minimizes trials that are duplicative
 - Best value for program – approving one trial per area in strategy
 - Ensures comparison of all submitted proposals together
- Areas of Caution:
 - Communication of process and expectations to field medical team and external customers
 - All eggs in one basket

Rolling Submissions

- Advantages:
 - High customer satisfaction
 - No need to wait to submit top priority trial
- Areas of Caution:
 - Could lead to greater number of similar trials
 - Cumbersome internal review process
 - Budget allocation and planning for the year

Industry Standard Representative Cross-Functional Review Committee



*ad hoc reviewers

Committee Review Assessment



GUIDING PRINCIPLES FOR REVIEW

- They need to address meaningful scientific and clinical objectives supported by valid study designs in which privacy rights, safety and welfare of the patients is of greatest importance
- Good tracking system necessary to identify overlap-(some cases legal/Managers)
- Ethical : Balancing the commitment to high ethical standards against the desire to maximize the investment value
- Promote transparency and disclosure
- Cannot be driven by marketing department (OIG office program guidance for pharmaceutical manufacturers)

Overview

Establish an IIT Strategy

Optimize Submission and Review Process

Define Contract milestones for smooth execution

Manage strong relationships with external investigators while maintain compliance

Conclusions

Contracting and milestones

- Best practice to have budget approved/contracted in the local currency to avoid fluctuations
 - Require detailed budget breakdown to allow FMV calculations
 - FMV analysis-use comparators, bench marking tool
 - work closely with compliance to establish ground rules for FMV, develop SOP
 - Exceptions – lack of comparators - different countries, processes etc.
 - Seek expertise from different departments
 - Subject matter experts
 - Certain costs not supported
 - equipment costs
 - limit on O/H costs
 - SOP important
- Detailed protocol and if any drug distribution/labeling costs
- Set clear expectations with finance

Contracting and milestones

- Milestone payment based on completion of aims in the protocol- hence detailed budget and protocol important
- Typically 4 milestone payments
 - contract execution (including non refundable costs like IRB submission, site start up, pharmacy start up)
 - 50% enrollment (patients)
 - 100% enrollment/last patient enrollment
 - submission of manuscript/final study report (last 10-15% of total budget)
- Modified as necessary depending on size and length of the study
- Study should be funded appropriately to move smoothly/complete on time

Contracting and milestones

- Creating multiple smaller milestones especially for large clinical trials
 - Breakdown bigger milestones into several smaller milestones payments ex execution of contract, submission and approval for Ethical Committee approval, activation of site/s, enrollment of first patient etc.
- These mitigate risks for budget planning as huge sum of money does not get blocked on one milestone
- Helps to clearly set expectations and budget management with finance
- Helpful with internal budget tracking-forecast and spent tracking
 - Consider using specific timelines in the contract for milestone payments

Study Objectives - {IIT STUDY NUMBER}

- Hypotheses:
- Primary/Secondary Objectives:
- Primary Endpoints:

Scientific/Medical Rationale for Study Support - {IIT STUDY NUMBER}



- Key Data Gap Addressed:

Investigator/Institution Qualifications- {IIT STUDY NUMBER}



- Summary of Investigators Qualifications/Experience in this Area of Research:

- Institution and Infrastructure Capabilities as it Relates to Feasibility of Completing the Study:

Overview

Establish an IIT Strategy

Optimize Submission and Review Process

Define Contract milestones for smooth execution

Manage strong relationships with external investigators while maintain compliance

Conclusions

EXTERNAL ENGAGEMENT – Prior To Submission

- AOI are communicated to PI via submission website – researcher facing
- RFP – launching product or higher priority proposals for unmet needs
 - Used as a tool to raise awareness
 - Work with various congresses to raise awareness for RFPs like a press release
- Field based personnel (MSLs) (based on detailed documents reviewed by compliance)
 - AOI
 - Future research/Treatments available

EXTERNAL ENGAGEMENT: Relationship Building

- Understanding the Investigators:
 - Local involvement important- MSL role central
 - Most Investigators are clinicians along with being researchers
 - Lack of time and administrative process patience
- Developing a good communication and feedback process:
 - Timely and friendly follow ups for efficient budget forecasting
 - Study Updates
 - Reinforcement of company processes and procedures
- Timely payments
 - Be sensitive to situations in external grant run Institutions

Overview

Establish an IIT Strategy

Optimize Submission and Review Process

Define Contract milestones for smooth execution

Manage strong relationships with external investigators while maintain compliance

Conclusions

Conclusions

- A well developed strategy created before submissions are received allows for the best, unbiased approach to IIT selection
- Both window and rolling submissions have their benefits and the best approach for your company should be taken
- Milestones based on individual study requirement, following basic guidelines lead to timely completion of study
- Strong relationships based on good communication with Investigators/Institutions in a compliant manner, leads to smooth execution of a study

Drug Supply challenges: Operational details

- Managing product life cycle for IIRs
 - Coordination with supply team
 - For global supplies- team structure may vary
- Forecasting of products for IIR trials
 - Forecast as soon as the study is approved
 - Master Planner/Supply Lead for particular product
- Any specific requirement for the product
 - Labeling needs per specific country
- Shipment needs for multi center trials
 - Central Pharmacy or direct shipment- Central pharmacy preferred
 - Central re-labeling before shipment
- Budget planning for such needs
- Product forecast/planning for short shelf life products for large multicenter trials

*Thank
You*



MAPS eCademy

Tweet @MAPSmedaffairs pre-, during and post-Webinar to keep the conversation going. Use #MAPSecademy

Share your best practices, questions & needs 24/7 via our online Forums in the MAPS Community Portal:
www.medicalaffairs.org/community



Questions?